person · Reporting owner

Collins Cynthia

Disclosed activity across 6 companies

Tapewire entity: 36312
SEC CIK: 0001405692

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CODEXIS, INC.CDXS · Entity 6428	Director	June 17, 2026	June 18, 2026
DermTech, Inc.DMTK · Entity 89998	Director	June 01, 2023	June 05, 2023
Editas Medicine, Inc.EDIT · Entity 5502	CEO	February 09, 2021	February 10, 2021
MAXCYTE, INC.MXCT · Entity 6608	Director	June 17, 2026	June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CODEXIS, INC.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2036-06-17	Direct	66,350	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 66,350 · Balance 66,350 F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests and becomes exercisable with respect to all of the shares subject to the award on the earlier of the first anniversary of the date of grant or the next annual stockholder meeting, subject to the director's continued service to the Company on such vesting date.

DermTech, Inc.

Report date June 01, 2023 · Filed June 05, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	104,835	Reported balance After 2023-06-01 transaction · row 1 1 source row Row 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 104,835 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on June 1, 2024.

Editas Medicine, Inc.

Report date February 09, 2021 · Filed February 10, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,760	Reported balance After 2021-02-09 transaction · row 1 1 source row Row 1 · 2021-02-09 · Sale · Disposed 1,262 · Balance 43,760 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2021. The sale does not represent a discretionary trade by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $66.47 to $66.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filing footnotes · ownership attribution and instrument terms

F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on May 11, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2021. The sale does not represent a discretionary trade by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $66.47 to $66.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

MAXCYTE, INC.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	111,310	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 30,421 · Balance 111,310 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2036-06-16	Direct	49,579	Reported balance After 2026-06-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-17 · Grant · Acquired 49,579 · Balance 49,579 F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Certara, Inc.

Report date May 14, 2026 · Filed May 15, 2026

Section 16 reporting ended · disclosed 2026-05-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	51,846	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Exercise / conversion · Acquired 15,757 · Balance 51,846 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Exercise / conversion · Disposed 15,757 · Balance 0 F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") was granted on May 21, 2025, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting.

Poseida Therapeutics, Inc.

Report date January 08, 2025 · Filed January 08, 2025

Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-01-08 transaction · row 1 1 source row Row 1 · 2025-01-08 · Other · Disposed 58,950 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2031-07-22	Direct	Reported balance After 2025-01-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-08 · Disposition to issuer · Disposed 87,440 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2032-06-15	Direct	Reported balance After 2025-01-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-01-08 · Disposition to issuer · Disposed 28,500 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2033-06-14	Direct	Reported balance After 2025-01-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.81 · Expires 2034-06-16	Direct	Reported balance After 2025-01-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-01-08 · Disposition to issuer · Disposed 27,350 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 19, 2019 Filed Aug 21, 2019 20:03 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantCommon Stock	8,283	$0.00	$0.00	Disclosure SEC source: 0001179110-19-009744 · edgar.xml · nonDerivative · entry 1 Collins Cynthia · CIK 0001405692 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,566 F1 · balance_after: The reported transaction involved the Reporting Peron's receipt of 8,283 shares of common stock on August 19, 2019 in connection with the vesting of a restricted stock unit award. Such amount includes (i) 8,283 shares of common stock received by the Reporting Person on August 19, 2019 that was previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 4, 2019 and (ii) 8,283 shares of common stock received by the Reporting Person in connection with a restricted stock unit award that was previously reported in Table 1 of a Form 4 filed by the Reporting Person with the SEC on August 7, 2019. Read SEC document
August 06, 2019 Filed Aug 7, 2019 20:16 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantCommon Stock	8,283	$0.00	$0.00	Disclosure SEC source: 0001179110-19-009249 · edgar.xml · nonDerivative · entry 1 Collins Cynthia · CIK 0001405692 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,566 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest in its entirety on the earlier of (i) the termination of the engagement of the Reporting Person as an interim Chief Executive Officer of Editas Medicine, Inc. and (ii) December 31, 2019. F1 · price: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest in its entirety on the earlier of (i) the termination of the engagement of the Reporting Person as an interim Chief Executive Officer of Editas Medicine, Inc. and (ii) December 31, 2019. F2 · balance_after: Such amount includes common stock to be received by the Reporting Person on or about August 19, 2019 in connection with the anticipated vesting of a Restricted Stock Unit award granted to the Reporting Person and previously reported on Table II of a Form 4 filed by the Reporting Person with the SEC on February 4, 2019. Read SEC document
June 12, 2019 Filed Jun 14, 2019 20:26 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	11,538	$0.00 Strike: $21.74	$0.00	Disclosure SEC source: 0001179110-19-007669 · edgar.xml · derivative · entry 1 Collins Cynthia · CIK 0001405692 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2019 and is scheduled to vest in full on June 12, 2020. Read SEC document
January 31, 2019 Filed Feb 4, 2019 22:36 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantRestricted Stock Units · Derivative	8,283	$0.00	$0.00	Disclosure SEC source: 0001179110-19-001239 · edgar.xml · derivative · entry 1 Collins Cynthia · CIK 0001405692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,283 Underlying: Common Stock · 8,283 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of common stock of Editas Medicine, Inc. F2 · derivative.exercise_date: The restricted stock unit award is scheduled to vest in its entirety on the earlier of (i) July 31, 2019, (ii) the appointment by the Board of Directors of Editas Medicine, Inc. (the "Company") of a permanent chief executive officer or (iii) the termination of a consulting agreement entered into by the Reporting Person and the Company (the "Trigger Date"). On the Trigger Date, all shares will be delivered to the Reporting Person. F2 · derivative.expiration_date: The restricted stock unit award is scheduled to vest in its entirety on the earlier of (i) July 31, 2019, (ii) the appointment by the Board of Directors of Editas Medicine, Inc. (the "Company") of a permanent chief executive officer or (iii) the termination of a consulting agreement entered into by the Reporting Person and the Company (the "Trigger Date"). On the Trigger Date, all shares will be delivered to the Reporting Person. Read SEC document
December 06, 2018 Filed Dec 10, 2018 14:14 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	23,076	$0.00 Strike: $29.69	$0.00	Disclosure SEC source: 0001179110-18-013609 · edgar.xml · derivative · entry 1 Collins Cynthia · CIK 0001405692 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,076 Underlying: Common Stock · 23,076 shares Expires 2028-12-05 F1 · derivative.exercise_date: This option was granted on December 6, 2018 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on December 6, 2019 through December 6, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.